An NHS Digital report reveals that prescriptions for the treatment of diabetes in primary care are rising at a much higher rate than overall prescribing, with an 80.1 per cent increase over the last decade compared to a 46 per cent rise across all prescription items. It also shows that diabetes drugs account for an increasing proportion of the total prescribing budget.

Prescribing for Diabetes: England 2006/07 to 2016/17 shows that 52 million items were prescribed for diabetes in 2016/17, up from 49.7 million in 2015/16 and 28.9 million in 2006/07.

The report shows that in 2016/17 the number of items prescribed for diabetes grew more than twice as fast (4.7 per cent) as the overall increase in prescriptions across primary care (2.0 per cent).

Rise in prescriptions

For the years where comparable figures are available, prescribing for diabetes in primary care has grown nearly twice as quickly as the rise in diabetes prevalence across the population, the report says. While the most recent prevalence figures show a 22.6 per cent increase in people living with diabetes between 2009/10 and 2015/16, primary care prescriptions for diabetes increased by 40 per cent during this period. Prescriptions for the most commonly prescribed category of diabetes drugs, Biguanides (metformin), rose by 51.5 per cent over this period.

While diabetes prescription items accounted for less than £1 in every £14 spent on primary care prescription items in 2006/07, in 2016/17 the share of overall spend was £1 in every £9.

Against a backdrop of an overall fall in the cost of primary care prescription items, the cost of diabetes drugs increased by £27 million between 2015/16 and 2016/17. For each year since 2007/08, Drugs Used in Diabetes has accounted for the highest cost of all British National Formulary (BNF) therapeutic areas since 2007/08.

Drugs classified as ‘other antidiabetic drugs’, which are often new to the market, are the most expensive category of drugs used in diabetes, for the first time overtaking the cost of human analogue insulin. They account for a low proportion of all items prescribed for diabetes, but that figure is rising. In 2016/17 they cost £322.5 million, compared with £103 million in 2006/07.

Originally Published by P3 Pharmacy

Recommended

New education standards for pharmacy technicians

The GPhC has launched new standards for the initial education and training of pharmacy technicians

GPhC welcomes positive PSA review

The GPhC has met all of the Professional Standards Authority’s standards for good regulation in 2016/17

Popular

Making habits last a lifetime

Falling activity levels in young people are deeply concerning, say experts, so what can be done to encourage youngsters ...

Raising awareness of pancreatic cancer

Public awareness of pancreatic cancer has been slow to catch up with other forms of the disease. So what is this devasta...

Taking on pancreatic cancer

Pancreatic Cancer Action chief executive Ali Stunt speaks to TM about the work the charity does to raise awareness of t...